Paracetamol and glycerol

Phase 3Small molecule

Paracetamol and glycerol is one of 7 small molecule programs targeting Bacterial Meningitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial MeningitisActive, not recruiting

Bacterial MeningitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Bacterial Meningitis

#DrugCompanyPhaseTrials

Tylenol

KKenvue Brands

Approved

—2

Avycaz

PPhiladelphia Eye Associates

Approved

—3

Merrem

BB. Braun Medical Inc.

Paracetamol

1 5

Glycerol

NNova Scotia Health Authority

Phase 3

1 6

Cubicin

BBaxter Healthcare Corporation

Phase 1

1 7

Paracetamol and glycerol

KKamuzu University of Health Sciences

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bacterial Meningitis1 trial

Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis

Completed·KKamuzu University of Health Sciences·Phase 3·NCT00619203·466 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Paracetamol and glycerol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paracetamol and glycerol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paracetamol and glycerol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kamuzu University of Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKamuzu University of Health Sciences

Paracetamol and glycerol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bacterial Meningitis1 trial

References

Drug Info

Quick Facts

Related News